Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05806931 · ClinicalTrials.gov registry record · Phase 2
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
A Phase 2 study of Colon Cancer and Rectal Cancer, sponsored by Rutgers, The State University of New Jersey.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 9
- Study locations
NCT05806931 is a Phase 2 study of Colon Cancer and Rectal Cancer that is actively recruiting participants, run by Rutgers, The State University of New Jersey. The registered enrollment target is 50 participants, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The trial reports 9 study locations across 1 state.
The verdict
NCT05806931, a Phase 2 study of Colon Cancer and Rectal Cancer, is actively recruiting participants, sponsored by Rutgers, The State University of New Jersey.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 9
- Study locations
Study Summary
This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizumab in late-line metastatic colorectal cancer (mCRC)
Conditions Studied
Interventions
- DRUG TAS-102, oxaliplatin, irinotecan with bevacizumab
Study Locations (9)
New Jersey
- Trinitas Hospital and Comprehensive Cancer Center - Elizabeth
- RWJBarnabas Health Jersey City Medical Center - Jersey City
- RWJBarnabas Health - Monmouth Medical Center Southern Campus - Lakewood
- Cooperman Barnabas Medical Center (Saint Barnabas Medical Center) - Livingston
- RWJBarnabas Health - Monmouth Medical Center - Long Branch
- Rutgers Cancer Institute of New Jersey - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - New Brunswick
- RWJBarnabas Health - Robert Wood Johnson University Hospital - Somerset
- RWJBarnabas Health - Community Medical Center - Toms River
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-05-17 |
| Est. Completion | 2027-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05806931
The ClinicalTrials.gov registry entry for NCT05806931 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,456-participant average among 97 other Colon Cancer trials with a reported enrollment target (99% lower). The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Colon Cancer appearing as the primary indexed condition, and to 1 intervention - of which TAS-102, oxaliplatin, irinotecan with bevacizumab is the first listed.
NCT05806931 reports 9 study locations spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT05806931 about?
NCT05806931 is a clinical study titled "Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer". This study is to evaluate the disease control rate and time to progression of the sequential combination of oxaliplatin with an alternative anti-metabolite Trifluridine/tipiracil hydrochloride mixture, TAS-102,(TAS-OX) as well as irinotecan in combination with TAS-102 oxaliplatin(TAS-OX) + Bevacizum...
What is the current status of trial NCT05806931?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2023-05-17. Estimated completion is 2027-05-01.
What conditions does trial NCT05806931 study?
This clinical trial studies the following conditions: Colon Cancer, Rectal Cancer.
What interventions are being tested in trial NCT05806931?
The interventions under investigation include: TAS-102, oxaliplatin, irinotecan with bevacizumab (DRUG).
Who is sponsoring clinical trial NCT05806931?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05806931 being conducted?
This trial has 9 study locations across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colon Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
RECRUITING · Phase 2
-
Phase II Trial of Lung Chemoemobolization
RECRUITING · Phase 2
-
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
RECRUITING · Phase 2
-
The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
RECRUITING · Phase 2
-
Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 2
-
Clinical Trial in Patients With Metastatic Colorectal Cancer
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.